C3 glomerulonephritis
MONDO:0013892Glomerulonephritis characterized by C3 accumulation with little or absent deposition of immunoglobulin, in the absence of ultrastructural electron-dense transformation seen in dense deposit disease.
Also known as: complement-mediated membranoproliferative glomerulonephritis, nephropathy due to CFHR5 deficiency, CFHR5 deficiency
10 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug aims to stop kidney disease from coming back after transplant
Disease control CompletedThis phase 2 study tested a drug called pegcetacoplan in 13 kidney transplant patients whose original kidney disease (C3G or IC-MPGN) had come back. The goal was to see if the drug could reduce signs of disease activity in the kidney. The study was small and early-stage, so resul…
Phase: PHASE2 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Hope for rare kidney patients: new drug shows promise in phase 3 trial
Disease control CompletedThis study tested a drug called pegcetacoplan in 124 adults and teens with two rare kidney diseases (C3G and IC-MPGN). The goal was to see if the drug could reduce protein in the urine, a sign of kidney damage. Participants received either the drug or a placebo twice a week for 2…
Phase: PHASE3 • Sponsor: Apellis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC